Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 8 Breast 7 Gastrointestinal 4 CNS 2 Tumor-Agnostic 1 Other solid neoplasm 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 55 Specimen Handling 28 Biopsy 28 Magnetic Resonance Spectroscopy 26 Paclitaxel 23 Blood Specimen Collection 22 Nivolumab 20 atezolizumab 18 Standard of Care 18 Carboplatin 18 Surveys and Questionnaires 17 Bevacizumab 17 Oxaliplatin 13 Fluorouracil 13 Cisplatin 13 Radiotherapy 12 Radiosurgery 12 Cyclophosphamide 12 Pemetrexed 11 Leucovorin 11 Irinotecan 10 Gemcitabine 10 Docetaxel 10 Capecitabine 10 trastuzumab deruxtecan 8 olaparib 8 durvalumab 8 Taxes 8 Ipilimumab 8 Trastuzumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

patritumab deruxtecan × Tumor-Agnostic × 1 year × Clear all

NCT06941272 2026-05-12

MK-9999-01C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡